Dataset Information

Dataset reporting detection of breast cancer-related HER2^I655V polymorphism using allele-specific polymerase chain reaction.

ABSTRACT: The dataset presented in this article is related to the research article entitled "Detection of HER2 Gene Polymorphism in Breast Cancer: PCR Optimization Study" (B.R. Budiarto, Desriani, 2016) [1] with some modification in primers used and in PCR optimization strategy to eliminate false-positive result that may occur in HER2^I655V polymorphism detection. Combining a new set of primers with PCR gradient, The allele-specific PCR well performs to detect all type of breast cancer-originated HER2^I655V genotypes. The validation of this method was done using Sanger DNA sequencing, offering an alternative tool for HER2^I655V polymorphism detection in another type of cancer.

SUBMITTER: Budiarto BR

PROVIDER: S-EPMC5072141 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Dataset reporting detection of breast cancer-related HER2I655V polymorphism using allele-specific polymerase chain reaction.

Budiarto Bugi Ratno BR Desriani

Data in brief 20160924

The dataset presented in this article is related to the research article entitled "Detection of HER2 Gene Polymorphism in Breast Cancer: PCR Optimization Study" (B.R. Budiarto, Desriani, 2016) [1] with some modification in primers used and in PCR optimization strategy to eliminate false-positive result that may occur in HER2I655V polymorphism detection. Combining a new set of primers with PCR gradient, The allele-specific PCR well performs to detect all type of br ...[more]

PMID: 27790634

Similar Datasets

Project description:Epithelial growth factor receptor (EGFR)-tyrosine kinase inhibitors are the standard first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) expressing sensitive EGFR-mutants. Other drugs target different driver mutants, including the serine/threonine-protein kinase B-raf (BRAF) inhibitor dabrafenib, which has exhibited promising efficacy for treating patients with metastatic BRAF-mutated NSCLC. Therefore, identifying patients carrying mutations that may be treated using targeted therapies is important. However, the methods of molecular detection presently applied in clinical practice, particularly detection of BRAF in NSCLC patients, require further investigation. Therefore, more sensitive and economic methods are required. The present study applied the competitive allele-specific TaqMan polymerase chain reaction (CastPCR) technology to the molecular detection of EGFR (del2235-2249, del2236-2250, T790M, L858R) and BRAF (V600E, G469A, D594G) mutations in 144 treatment-naive patients with lung adenocarcinoma, and analyzed the association between the mutation rates and patients' clinicopathological features. 51.4% (74/144) cases were identified harboring EGFR mutations. A total of 40.3% (58/144) patients carried sensitizing mutations (exon 19 deletion or L858R) and 14.6% (21/144) carried T790M mutations. 6.9% (10/144) mutation-positive patients were double-mutated. Total EGFR mutation rate was significantly increased in female compared with that of males (60.9 vs. 43.8%, P<0.05), in non-smokers compared with that of smokers (62.8 vs. 34.5%, P<0.05). In total, 8.3% (12/144) patients were identified with BRAF mutations. 16.7% were V600E (2/12) and 83.3% (10/12) were non-V600E mutants. Among the 10 non-V600E mutations, D594G accounted for 90.0% (9/10) and G469A accounted for 10.0% (1/10). Statistical analysis demonstrated that the BRAF mutation rate was not associated with any of the following clinicopathological features: Sex, age, smoking history, clinical stages, distant metastasis, differentiation degree, tumor size and regional lymph node metastasis (P≥0.05). CastPCR technology is a robust method with high sensitivity for the molecular detection of EGFR and BRAF mutations in clinical formalin-fixed paraffin-embedded samples.

Dataset Information

Dataset reporting detection of breast cancer-related HER2^I655V polymorphism using allele-specific polymerase chain reaction.

Publications

Dataset reporting detection of breast cancer-related <i>HER2</i><sup><i>I655V</i></sup> polymorphism using allele-specific polymerase chain reaction.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets